Identification

Name
Cefuroxime
Accession Number
DB01112  (APRD00285)
Type
Small Molecule
Groups
Approved
Description

Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

Structure
Thumb
Synonyms
  • (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • Cefuroxim
  • Cefuroxima
  • Cefuroxime
  • Cefuroximo
  • Cefuroximum
  • Cephuroxime
Product Ingredients
IngredientUNIICASInChI Key
Cefuroxime axetilZ49QDT0J8Z64544-07-6KEJCWVGMRLCZQQ-YJBYXUATSA-N
Cefuroxime sodiumR8A7M9MY6156238-63-2URDOHUPGIOGTKV-JTBFTWTJSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CeftinPowder, for suspension250 mg/5mLOralA S Medication Solutions2004-06-02Not applicableUs
CeftinPowder, for suspension250 mg/5mLOralGlaxosmithkline Inc2004-06-022018-09-30Us
CeftinTablet, film coated250 mg/1OralGlaxosmithkline Inc1989-10-012018-04-30Us00173 0387 00 nlmimage10 8018c066
CeftinTablet, film coated250 mg/1OralPhysicians Total Care, Inc.1989-10-012012-06-30Us
CeftinPowder, for suspension125 mg/5mLOralGlaxosmithkline Inc2004-06-022018-09-30Us
Ceftin - Pwr 250mg/sachetPowder250 mgOralGlaxosmithkline Inc1999-11-102003-02-07Canada
Ceftin - Pws 125mg/5mlPowder, for solution125 mgOralGlaxosmithkline Inc1999-09-13Not applicableCanada
Ceftin - Tab 250mgTablet250 mgOralGlaxosmithkline Inc1998-12-31Not applicableCanada
Ceftin - Tab 500mgTablet500 mgOralGlaxosmithkline Inc1998-10-27Not applicableCanada
Ceftin for Oral Suspension-pws 250mg/pckPowder, for solution250 mgOralGlaxo Canada Inc1995-12-312000-08-02Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cefuroximeTablet500 mgOralApotex Corporation2001-08-29Not applicableCanada
Apo-cefuroximeTablet250 mgOralApotex Corporation2001-08-29Not applicableCanada
Auro-cefuroximeTablet250 mgOralAurobindo Pharma Limited (Unit Vi)2012-01-13Not applicableCanada
Auro-cefuroximeTablet500 mgOralAurobindo Pharma Limited (Unit Vi)2012-01-13Not applicableCanada
CefuroximeInjection, powder, for solution1.5 g/1IntravenousWest Ward Pharmaceutical2004-01-09Not applicableUs
CefuroximeInjection, powder, for solution750 mg/100mLIntravenousWG Critical Care, LLC2012-10-04Not applicableUs
CefuroximeInjection, powder, for solution90 mg/1mLIntravenousHospira, Inc.2009-04-272013-12-01Us
CefuroximeInjection, powder, for solution1.5 g/100mLIntravenousWG Critical Care, LLC2012-10-04Not applicableUs
CefuroximeInjection, powder, for solution1.5 g/1IntravenousWest Ward Pharmaceutical2004-01-09Not applicableUs
CefuroximeInjection, powder, for solution7.5 g/82.5mLIntravenousSagent Pharmaceuticals2008-05-012014-12-31Us
International/Other Brands
Cefurax (Lindopharm) / Elobact (GlaxoSmithKline) / Oraxim (Malesci) / Sharox (Fahrenheit) / Supacef (GlaxoSmithKline) / Zinacef danmark / Zinnat (GlaxoSmithKline)
Categories
UNII
O1R9FJ93ED
CAS number
55268-75-2
Weight
Average: 424.385
Monoisotopic: 424.068884198
Chemical Formula
C16H16N4O8S
InChI Key
JFPVXVDWJQMJEE-IZRZKJBUSA-N
InChI
InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
IUPAC Name
(6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O

Pharmacology

Indication

For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.

Associated Conditions
Pharmacodynamics

Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi. Cefuroxime axetil is the prodrug

Mechanism of action

Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.

TargetActionsOrganism
APenicillin-binding protein 1A
inhibitor
Clostridium perfringens (strain 13 / Type A)
Absorption

Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).

Volume of distribution
Not Available
Protein binding

50% to serum protein

Metabolism

The axetil moiety is metabolized to acetaldehyde and acetic acid.

Route of elimination
Not Available
Half life

Approximately 80 minutes following intramuscular or intravenous injection.

Clearance
Not Available
Toxicity

Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Cefuroxime is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Cefuroxime is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Cefuroxime is combined with 4-hydroxycoumarin.
AbacavirCefuroxime may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseCefuroxime may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacCefuroxime may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefuroxime is combined with Acenocoumarol.
AcetaminophenCefuroxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefuroxime.
Food Interactions
  • Take with food to increase absorption.

References

Synthesis Reference

Vijay Kumar Handa, Ramesh Dandala, Jag Mohan Khanna, "Process for the preparation of cefuroxime." U.S. Patent US6235896, issued February, 1976.

US6235896
General References
  1. Perry CM, Brogden RN: Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996 Jul;52(1):125-58. [PubMed:8799689]
External Links
Human Metabolome Database
HMDB0015244
KEGG Drug
D00262
KEGG Compound
C06894
PubChem Compound
5479529
PubChem Substance
46506681
ChemSpider
4586393
BindingDB
50422689
ChEBI
3515
ChEMBL
CHEMBL1436
Therapeutic Targets Database
DAP000445
PharmGKB
PA448868
HET
KOV
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Cefuroxime
ATC Codes
S01AA27 — CefuroximeJ01DC02 — CefuroximeJ01RA03 — Cefuroxime and metronidazole
AHFS Codes
  • 08:12.06.08 — Second Generation Cephalosporins
PDB Entries
4kov
FDA label
Download (809 KB)
MSDS
Download (52.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionComplications of Surgical Procedures1
0RecruitingTreatmentOsteomyelitis1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
3CompletedPreventionAppendicitis Acute / Perforated Gastroduodenal Ulcer / Small intestinal obstruction1
3CompletedTreatmentPneumonia1
3RecruitingTreatmentEnterobacteriaceae Infections1
4Active Not RecruitingTreatmentInfection NOS1
4CompletedPreventionInfection NOS1
4CompletedPreventionInfection Prophylaxis in Colo Rectal Surgery1
4CompletedPreventionInfection, Postoperative Wound1
4CompletedPreventionObesity; Drug1
4CompletedPreventionPostoperative Infections1
4CompletedPreventionSurgical Site Infections1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
4CompletedTreatmentComplications; Cesarean Section / Infection, Postoperative Wound / Infection; Cesarean Section1
4CompletedTreatmentErythema Chronicum Migrans / Post-Lyme Disease Symptoms1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentWound Infections1
4RecruitingHealth Services ResearchAntibiotic Resistant Infection / Uncomplicated Urinary Tract Infections1
4RecruitingPreventionInfection, Postoperative Wound1
4WithdrawnTreatmentPostoperative Infections1
Not AvailableCompletedPreventionEndophthalmitis1
Not AvailableCompletedSupportive CareOsteoarthritis (OA) / Post-traumatic; Arthrosis1
Not AvailableCompletedTreatmentCataracts / Endophthalmitis1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableNot Yet RecruitingNot AvailableCardiovascular Events1
Not AvailableUnknown StatusPreventionCystocele / Enterocele / Rectocele / Uterine Prolapse1
Not AvailableUnknown StatusPreventionInfection NOS1
Not AvailableUnknown StatusPreventionPeristomal Wound Infection After the Operation of PEG / Prophylactic Antibiotics Before PEG / The Patients Who Receive Percutaneous Endoscopic Gastrostomy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • BMH Ltd.
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Cura Pharmaceutical Co. Inc.
  • DAVA Pharmaceuticals
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • Elan Pharmaceuticals Inc.
  • Eli Lilly & Co.
  • F Hoffmann-La Roche Ltd.
  • Forum Products Inc.
  • GC Hanford Manufacturing Co.
  • GlaxoSmithKline Inc.
  • Greenstone LLC
  • Hikma Pharmaceuticals
  • Hospira Inc.
  • Liberty Pharmaceuticals
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • Orchid Healthcare
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Sagent Pharmaceuticals
  • Samson Medical Technologies
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
  • World Gen LLC
  • Zyber Pharmaceuticals
Dosage forms
FormRouteStrength
Powder, for suspensionOral125 mg/5mL
Powder, for suspensionOral250 mg/5mL
PowderOral250 mg
Powder, for solutionOral125 mg
TabletOral250 mg
TabletOral500 mg
Powder, for solutionOral250 mg
Injection, powder, for solutionIntramuscular; Intravenous750 mg/1
Injection, powder, for solutionIntravenous1.5 g/16mL
Injection, powder, for solutionIntravenous1.5 g/1
Injection, powder, for solutionIntravenous1.5 g/100mL
Injection, powder, for solutionIntravenous7.5 g/1
Injection, powder, for solutionIntravenous7.5 g/82.5mL
Injection, powder, for solutionIntravenous7.5 g/80mL
Injection, powder, for solutionIntravenous750 mg/8mL
Injection, powder, for solutionIntravenous750 mg/100mL
Injection, powder, for solutionIntravenous90 mg/1mL
Injection, powder, for solutionIntravenous95 mg/1mL
TabletOral125 mg/1
TabletOral250 mg/1
TabletOral500 mg/1
Tablet, film coatedOral125 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
SuspensionOral125 mg/5mL
SuspensionOral250 mg/1mL
Powder, for solutionIntravenous7.5 g
Powder, for solutionIntravenous750 mg
Injection, powder, for solutionIntravenous225 g/1
Injection, powder, for solutionIntravenous75 g/1
Powder, for solutionIntravenous1.5 g
TabletOral125 mg
Injection, powder, for solutionIntramuscular; Intravenous750 mg/8.3mL
Injection, powder, for solutionIntramuscular; Intravenous90 mg/1mL
Injection, powder, for solutionIntravenous7.5 g/77mL
Injection, powder, for solutionIntravenous750 mg/8.3mL
Injection, powder, lyophilized, for solutionIntravenous1.5 g/1
Injection, powder, lyophilized, for solutionIntravenous750 mg/1
Injection, solutionIntravenous1.5 g/50mL
Injection, solutionIntravenous750 mg/50mL
Powder, for solutionIntramuscular; Intravenous1.5 g
Powder, for solutionIntramuscular; Intravenous750 mg
Prices
Unit descriptionCostUnit
Rocephin 10 gm vial478.32USD vial
Ceftin 20 500 mg tablet Bottle436.36USD bottle
Cefuroxime Axetil 250 mg/5ml Suspension 100ml Bottle121.27USD bottle
Rocephin 2 gm vial97.5USD vial
Cefzil 250 mg/5ml Suspension 100ml Bottle87.62USD bottle
Zinacef 7.5 gm vial65.94USD vial
Rocephin 1 gm Solution Vial65.53USD vial
Rocephin 1 gm vial62.02USD vial
Duricef 500 mg/5ml Suspension 100ml Bottle59.36USD bottle
Cefzil 125 mg/5ml Suspension 100ml Bottle48.36USD bottle
Duricef 500 mg/5ml Suspension 75ml Bottle46.93USD bottle
Maxipime 2 gram vial43.04USD vial
Velosef 250 mg/5ml Suspension 100ml Bottle23.99USD bottle
Maxipime 1 gm piggyback vial23.24USD vial
Duricef 250 mg/5ml Suspension 50ml Bottle22.99USD bottle
Maxipime 1 gram vial21.7USD vial
Ceftin 500 mg tablet20.98USD tablet
Cefuroxime 1.5 g/50 ml bag16.8USD each
Cedax 400 mg capsule16.13USD each
Zinacef 1.5 gm add-vant vial13.94USD vial
Zinacef 1.5 gm vial13.45USD vial
Cefuroxime sod 1.5 gm vial13.44USD vial
Ceftin 250 mg tablet11.74USD tablet
Cefzil 500 mg tablet9.77USD tablet
Cefuroxime axetil 500 mg tablet8.11USD tablet
Duricef 1 gm tablet7.35USD tablet
Cefzil 250 mg tablet4.76USD tablet
Ceftin 500 mg Tablet3.61USD tablet
Cefuroxime axetil 250 mg tablet2.82USD tablet
Velosef 500 mg capsule2.02USD capsule
Apo-Cefuroxime 500 mg Tablet2.02USD tablet
Ratio-Cefuroxime 500 mg Tablet2.02USD tablet
Ceftin 250 mg Tablet1.82USD tablet
Velosef 250 mg capsule1.03USD capsule
Apo-Cefuroxime 250 mg Tablet1.02USD tablet
Ratio-Cefuroxime 250 mg Tablet1.02USD tablet
Zinacef-water 1.5 gm/50 ml0.32USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2408198No2004-03-092022-11-21Canada
CA1328405No1994-04-122011-04-12Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)218-225 °CNot Available
water solubilityFreely soluble as sodium salt (145 mg/L)Not Available
logP-0.16SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.284 mg/mLALOGPS
logP-0.24ALOGPS
logP-0.9ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.15ChemAxon
pKa (Strongest Basic)-1.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area173.76 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity97.17 m3·mol-1ChemAxon
Polarizability38.75 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6504
Blood Brain Barrier-0.9863
Caco-2 permeable-0.7051
P-glycoprotein substrateSubstrate0.7253
P-glycoprotein inhibitor INon-inhibitor0.8621
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8688
CYP450 2C9 substrateNon-substrate0.8686
CYP450 2D6 substrateNon-substrate0.8196
CYP450 3A4 substrateSubstrate0.5051
CYP450 1A2 substrateNon-inhibitor0.6957
CYP450 2C9 inhibitorNon-inhibitor0.7771
CYP450 2D6 inhibitorNon-inhibitor0.8707
CYP450 2C19 inhibitorNon-inhibitor0.7064
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8916
Ames testNon AMES toxic0.7525
CarcinogenicityNon-carcinogens0.8816
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity1.6593 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9724
hERG inhibition (predictor II)Non-inhibitor0.8292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephalosporin 3'-carbamates. These are cephalosporins that are substituted at the 3'-position by a carbamate group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporin 3'-carbamates
Alternative Parents
N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Tertiary carboxylic acid amides / Carbamate esters / Furans / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Organic carbonic acids and derivatives / Thiohemiaminal derivatives
show 10 more
Substituents
Cephalosporin 3'-carbamate / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / Meta-thiazine / Furan / Heteroaromatic compound / Carbamic acid ester / Tertiary carboxylic acid amide / Azetidine / Carboxamide group
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oxime O-ether, furans, 3-(carbamoyloxymethyl)cephalosporin (CHEBI:3515)

Targets

Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring glycosyl groups
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
pbpA
Uniprot ID
Q8XJ01
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
75176.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Cornaglia G, Ligozzi M, Bauernfeind A, Satta G, Fontana R: PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli. New Microbiol. 1994 Jul;17(3):203-10. [PubMed:7968655]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]

Drug created on June 13, 2005 07:24 / Updated on November 18, 2018 04:49